Joseph Lykins1, Kanix Wang2, Kelsey Wheeler3, Fatima Clouser3, Ashtyn Dixon3, Kamal El Bissati3, Ying Zhou3, Christopher Lyttle4, Andrey Rzhetsky5, Rima McLeod6. 1. Pritzker School of Medicine. 2. Committee on Genetics, Genomics, and Systems Biology. 3. Department of Ophthalmology and Visual Sciences. 4. Center for Health and Social Sciences (CHeSS). 5. Department of Medicine Department of Human Genetics Computation Institute. 6. Department of Ophthalmology and Visual Sciences Department of Pediatrics (Infectious Diseases), Institute of Genomics, Genetics, and Systems Biology, Global Health Center, Toxoplasmosis Center, CHeSS, The College, University of Chicago, Illinois.
Abstract
BACKGROUND: Toxoplasma gondii infection causes substantial morbidity and mortality in the United States, and infects approximately one-third of persons globally. Clinical manifestations vary. Seropositivity is associated with neurologic diseases and malignancies. There are few objective data concerning US incidence and distribution of toxoplasmosis. METHODS: Truven Health MarketScan Database and International Classification of Diseases, Ninth Revision (ICD-9) codes, including treatment specific to toxoplasmosis, identified patients with this disease. Spatiotemporal distribution and patterns of disease manifestation were analyzed. Comorbidities between patients and matched controls were compared. RESULTS: Between 2003 and 2012, 9260 patients had ICD-9 codes for toxoplasmosis. This database of patients with ICD-9 codes includes 15% of those in the United States, excluding patients with no or public insurance. Thus, assuming that demographics do not change incidence, the calculated total is 61 700 or 6856 patients per year. Disease was more prevalent in the South. Mean age at diagnosis was 37.5 ± 15.5 years; 2.4% were children aged 0-2 years, likely congenitally infected. Forty-one percent were male, and 73% of women were of reproductive age. Of identified patients, 38% had eye disease and 12% presented with other serious manifestations, including central nervous system and visceral organ damage. Toxoplasmosis was statistically associated with substantial comorbidities, including human immunodeficiency virus, autoimmune diseases, and neurologic diseases. CONCLUSIONS: Toxoplasmosis causes morbidity and mortality in the United States. Our analysis of private insurance records missed certain at-risk populations and revealed fewer cases of retinal disease than previously estimated, suggesting undercoding, underreporting, undertreating, or differing demographics of those with eye disease. Mandatory reporting of infection to health departments and gestational screening could improve care and facilitate detection of epidemics and, thereby, public health interventions.
BACKGROUND:Toxoplasma gondii infection causes substantial morbidity and mortality in the United States, and infects approximately one-third of persons globally. Clinical manifestations vary. Seropositivity is associated with neurologic diseases and malignancies. There are few objective data concerning US incidence and distribution of toxoplasmosis. METHODS: Truven Health MarketScan Database and International Classification of Diseases, Ninth Revision (ICD-9) codes, including treatment specific to toxoplasmosis, identified patients with this disease. Spatiotemporal distribution and patterns of disease manifestation were analyzed. Comorbidities between patients and matched controls were compared. RESULTS: Between 2003 and 2012, 9260 patients had ICD-9 codes for toxoplasmosis. This database of patients with ICD-9 codes includes 15% of those in the United States, excluding patients with no or public insurance. Thus, assuming that demographics do not change incidence, the calculated total is 61 700 or 6856 patients per year. Disease was more prevalent in the South. Mean age at diagnosis was 37.5 ± 15.5 years; 2.4% were children aged 0-2 years, likely congenitally infected. Forty-one percent were male, and 73% of women were of reproductive age. Of identified patients, 38% had eye disease and 12% presented with other serious manifestations, including central nervous system and visceral organ damage. Toxoplasmosis was statistically associated with substantial comorbidities, including human immunodeficiency virus, autoimmune diseases, and neurologic diseases. CONCLUSIONS:Toxoplasmosis causes morbidity and mortality in the United States. Our analysis of private insurance records missed certain at-risk populations and revealed fewer cases of retinal disease than previously estimated, suggesting undercoding, underreporting, undertreating, or differing demographics of those with eye disease. Mandatory reporting of infection to health departments and gestational screening could improve care and facilitate detection of epidemics and, thereby, public health interventions.
Authors: B Wong; J W Gold; A E Brown; M Lange; R Fried; M Grieco; D Mildvan; J Giron; M L Tapper; C W Lerner Journal: Ann Intern Med Date: 1984-01 Impact factor: 25.391
Authors: M Wallon; F Peyron; C Cornu; S Vinault; M Abrahamowicz; C Bonithon Kopp; C Binquet Journal: Clin Infect Dis Date: 2013-01-29 Impact factor: 9.079
Authors: Cynthia P Wyman; Shawn D Gale; Ariana Hedges-Muncy; Lance D Erickson; Eric Wilson; Dawson W Hedges Journal: Neurobiol Aging Date: 2017-02-03 Impact factor: 4.673
Authors: Cosme Alvarado-Esquivel; Edith Maldonado-Soto; Luis Francisco Sanchez-Anguiano; Jesus Hernandez-Tinoco; Agar Ramos-Nevarez; Sandra Margarita Cerrillo-Soto; Ada Agustina Sandoval-Carrilo; Jose Manuel Salas-Pacheco; Elizabeth Irasema Antuna-Salcido; Sergio Estrada-Martinez; Carlos Alberto Guido-Arreola Journal: Int J Biomed Sci Date: 2017-06
Authors: Ian J Begeman; Joseph Lykins; Ying Zhou; Bo Shiun Lai; Pauline Levigne; Kamal El Bissati; Kenneth Boyer; Shawn Withers; Fatima Clouser; A Gwendolyn Noble; Peter Rabiah; Charles N Swisher; Peter T Heydemann; Despina G Contopoulos-Ioannidis; Jose G Montoya; Yvonne Maldonado; Raymund Ramirez; Cindy Press; Eileen Stillwaggon; François Peyron; Rima McLeod Journal: PLoS Negl Trop Dis Date: 2017-06-26
Authors: Martin J McPhillie; Ying Zhou; Mark R Hickman; James A Gordon; Christopher R Weber; Qigui Li; Patty J Lee; Kangsa Amporndanai; Rachel M Johnson; Heather Darby; Stuart Woods; Zhu-Hong Li; Richard S Priestley; Kurt D Ristroph; Scott B Biering; Kamal El Bissati; Seungmin Hwang; Farida Esaa Hakim; Sarah M Dovgin; Joseph D Lykins; Lucy Roberts; Kerrie Hargrave; Hua Cong; Anthony P Sinai; Stephen P Muench; Jitender P Dubey; Robert K Prud'homme; Hernan A Lorenzi; Giancarlo A Biagini; Silvia N Moreno; Craig W Roberts; Svetlana V Antonyuk; Colin W G Fishwick; Rima McLeod Journal: Front Cell Infect Microbiol Date: 2020-06-09 Impact factor: 5.293
Authors: Huân M Ngô; Ying Zhou; Hernan Lorenzi; Kai Wang; Taek-Kyun Kim; Yong Zhou; Kamal El Bissati; Ernest Mui; Laura Fraczek; Seesandra V Rajagopala; Craig W Roberts; Fiona L Henriquez; Alexandre Montpetit; Jenefer M Blackwell; Sarra E Jamieson; Kelsey Wheeler; Ian J Begeman; Carlos Naranjo-Galvis; Ney Alliey-Rodriguez; Roderick G Davis; Liliana Soroceanu; Charles Cobbs; Dennis A Steindler; Kenneth Boyer; A Gwendolyn Noble; Charles N Swisher; Peter T Heydemann; Peter Rabiah; Shawn Withers; Patricia Soteropoulos; Leroy Hood; Rima McLeod Journal: Sci Rep Date: 2017-09-13 Impact factor: 4.379
Authors: Joseph D Lykins; Ekaterina V Filippova; Andrei S Halavaty; George Minasov; Ying Zhou; Ievgeniia Dubrovska; Kristin J Flores; Ludmilla A Shuvalova; Jiapeng Ruan; Kamal El Bissati; Sarah Dovgin; Craig W Roberts; Stuart Woods; Jon D Moulton; Hong Moulton; Martin J McPhillie; Stephen P Muench; Colin W G Fishwick; Elisabetta Sabini; Dhanasekaran Shanmugam; David S Roos; Rima McLeod; Wayne F Anderson; Huân M Ngô Journal: Front Cell Infect Microbiol Date: 2018-10-05 Impact factor: 5.293
Authors: Carlos A Gomez; Laura N Budvytyte; Cindy Press; Lily Zhou; Rima McLeod; Yvonne Maldonado; Jose G Montoya; Despina G Contopoulos-Ioannidis Journal: Open Forum Infect Dis Date: 2018-10-29 Impact factor: 3.835